Review, Jul/22: Barriers & enablers for deprescribing benzo receptor agonists...

The full title of this French/Belgian review is "Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework".

https://pubmed.ncbi.nlm.nih.gov/35804428/

Abstract

Background: Many strategies aimed at deprescribing benzodiazepine receptor agonists (BZRA) in older adults have already been evaluated with various success rates. There is so far no consensus on which strategy components increase deprescribing the most. Yet, despite an unfavourable benefit-to-risk ratio, BZRA use among older adults remains high. We systematically reviewed barriers and enablers for BZRA deprescribing in older adults.

Methods: Two reviewers independently screened records identified from five electronic databases-Medline, Embase, PsycINFO, CINAHL and the Cochrane library-and published before October 2020. They searched for grey literature using Google Scholar. Qualitative and quantitative records reporting data on the attitudes of older adults, caregivers and healthcare providers towards BZRA deprescribing were included. Populations at the end of life or with specific psychiatric illness, except for dementia, were excluded. The two reviewers independently assessed the quality of the included studies using the mixed-methods appraisal tool. Barriers and enablers were identified and then coded into domains of the theoretical domains framework (TDF) using a combination of deductive and inductive qualitative analysis. The most relevant TDF domains for BZRA deprescribing were then identified.

Results: Twenty-three studies were included 13 quantitative, 8 qualitative and 2 mixed-method studies. The points of view of older adults, general practitioners and nurses were reported in 19, 9 and 3 records, respectively. We identified barriers and enablers in the majority of TDF domains and in two additional themes: "patient characteristics" and "BZRA prescribing patterns". Overall, the most relevant TDF domains were "beliefs about capabilities", "beliefs about consequences", "environmental context and resources", "intention", "goals", "social influences", "memory, attention and decision processes". Perceived barriers and enablers within domains differed across settings and across stakeholders.

Conclusion: The relevant TDF domains we identified can now be linked to behavioural change techniques to help in the design of future strategies and health policies. Future studies should also assess barriers and enablers perceived by under-evaluated stakeholders (such as pharmacists, psychiatrists and health care professionals in the hospital setting).

Trial registration: This work was registered on PROSPERO under the title "Barriers and enablers to benzodiazepine receptor agonists deprescribing".

Registration number: CRD42020213035.

Full Paper:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264665/

Thank you, Intrepid Researcher Lapis2!

It’s unfortunate researchers don’t ask individuals who are trying to discontinue these drugs about barriers. I suspect lack of prescriber knowledge to help patients withdraw in a safe and humane manner would be one.  Another might be lack of access to safe, effective, and affordable medication dosage forms/strengths to enable accurate ‘small enough’ reductions in dose.

Thank you, Intrepid Researcher Lapis2!

 

It’s unfortunate researchers don’t ask individuals who are trying to discontinue these drugs about barriers. I suspect lack of prescriber knowledge to help patients withdraw in a safe and humane manner would be one.  Another might be lack of access to safe, effective, and affordable medication dosage forms/strengths to enable accurate ‘small enough’ reductions in dose.

Hi Libertas,

I think many of us on BB have the type of intimate knowledge of this topic that a review such as this would not pick up on.